title: Targeting dendritic cells in situ for breast cancer immunotherapy.
abstract: We have recently developed a protein vaccine against breast cancer in which HER2 is delivered to dendritic cells (DCs) in vivo through receptors expressed on their surface. Our results indicate that this is a promising approach to induce durable, broad and integrated immunity against breast cancer.
authors.affiliation: Laboratory of Cellular Physiology and Immunology and Chris Browne Center of Immunology and Immune Disease; The Rockefeller University; New York, NY USA.
authors.forename: Bei
authors.initials: B
authors.lastname: Wang